John H. Alexander - Concepedia

Author

John H. Alexander

Also Known As

, ALEXANDER, J, Alexander Iribarne, Alexander, John H., Christopher Dyke, Eric J.G. Sijbrands, J ALEXANDER, J Alexander, J H Alexander, J O H N Alexander

801

Publications

43.4K

Citations

104

H-Index

174

Concepts

All Affiliations

Clinical Research Institute Duke Medical Center Duke University Uppsala University Bristol-Myers Squibb (United States)

About

John H. Alexander is an author at Clinical Research Institute specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	8	8	288
2	Health Sciences	4	4	146
3	Language Studies	3	3	41
4	Education	1	1	10
5	Humanities	1	1	12

John H. Alexander

294

Publications

36.9K

Citations

H-Index

Page 1

	Year	Citations
Apixaban versus Warfarin in Patients with Atrial Fibrillation Christopher B. Granger, John H. Alexander, John J.V. McMurray, New England Journal of Medicine	2011	8.8K
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation Renato D. Lópes, Gretchen Heizer, Ronald Aronson, New England Journal of Medicine	2019	1.1K
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, JAMA	2018	1K
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome John H. Alexander, Renato D. Lópes, Stefan James, New England Journal of Medicine	2011	994
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Stefan H. Hohnloser, Ziad Hijazi, Laine Thomas, European Heart Journal	2012	564
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	516
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado, The Lancet ThrombosisCovid-19 PandemicPatient SafetyClinical TrialsAntiviral Therapy	2021	489
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study Ziad Hijazi, Jonas Oldgren, Johan Lindbäck, The Lancet Acute Myocardial InfarctionThrombosisStrokeNovel Biomarker-based AbcBleeding Disorder	2016	474
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome John H. Alexander, Richard C. Becker, Deepak L. Bhatt, Circulation	2009	460

Page 1